Hypera S.A. (HYPMY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hypera S.A. (HYPMY) with AI Score 45/100 (Weak). Hypera S. A. is a leading Brazilian pharmaceutical company with a diverse portfolio of branded prescription, consumer health, and generic products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Hypera S.A. (HYPMY) Healthcare & Pipeline Overview
Hypera S.A., based in Brazil, is a pharmaceutical company focused on branded prescription drugs, consumer health products, and generics. With a diverse portfolio including well-known brands like Benegrip and Addera, Hypera leverages its established distribution network and brand recognition to maintain a strong presence in the competitive Brazilian pharmaceutical market, demonstrating a P/E ratio of 11.78 and a dividend yield of 5.30%.
Investment Thesis
Hypera S.A. presents a notable research candidate due to its strong market position in the Brazilian pharmaceutical industry and diversified product portfolio. With a P/E ratio of 11.78 and a dividend yield of 5.30%, the company demonstrates financial stability and potential for shareholder returns. Key value drivers include the continued growth of its branded prescription and consumer health segments, expansion into new therapeutic areas, and strategic acquisitions. The company's established distribution network and brand recognition provide a competitive advantage. However, investors may want to evaluate potential risks such as regulatory changes, currency fluctuations, and competition from other pharmaceutical companies. The company's beta of 0.20 indicates low volatility compared to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $2.68 billion, reflecting its significant presence in the Brazilian pharmaceutical market.
- P/E ratio of 11.78, indicating a potentially undervalued stock compared to its earnings.
- Profit margin of 15.5%, demonstrating efficient operations and profitability.
- Gross margin of 57.7%, showcasing strong pricing power and cost management.
- Dividend yield of 5.30%, offering an attractive income stream for investors.
Competitors & Peers
Strengths
- Diversified product portfolio across multiple segments.
- Strong brand recognition and customer loyalty.
- Extensive distribution network throughout Brazil.
- Experienced management team.
Weaknesses
- Dependence on the Brazilian market.
- Exposure to currency fluctuations.
- Competition from larger multinational pharmaceutical companies.
- Regulatory risks and pricing pressures.
Catalysts
- Ongoing: Expansion of product portfolio through strategic acquisitions and licensing agreements.
- Ongoing: Growth in the consumer health segment driven by innovative product launches.
- Ongoing: Geographic expansion within Brazil targeting underserved regions.
- Upcoming: Potential regulatory changes in the Brazilian pharmaceutical market that could benefit Hypera.
- Upcoming: Launch of new dermo-cosmetic products under the Mantecorp Skincare brand in Q3 2026.
Risks
- Ongoing: Exposure to currency fluctuations between the U.S. dollar and the Brazilian real.
- Ongoing: Competition from larger multinational pharmaceutical companies.
- Potential: Changes in government regulations and healthcare policies in Brazil.
- Potential: Patent expirations and loss of exclusivity on key products.
- Potential: Economic downturn in Brazil impacting consumer spending on healthcare products.
Growth Opportunities
- Expansion of Branded Prescription Portfolio: Hypera can drive growth by expanding its portfolio of branded prescription drugs through strategic acquisitions and in-licensing agreements. Focusing on high-growth therapeutic areas such as cardiology, dermatology, and neurology can increase revenue and market share. The Brazilian prescription drug market is projected to reach $30 billion by 2028, offering substantial growth potential for Hypera.
- Strengthening Consumer Health Segment: Hypera can further strengthen its consumer health segment by introducing innovative over-the-counter products and expanding its distribution network. Focusing on categories such as pain relief, cough and cold, and vitamins and supplements can drive revenue growth. The Brazilian consumer health market is estimated at $15 billion, providing ample opportunity for Hypera to increase its market presence.
- Geographic Expansion within Brazil: Hypera can expand its geographic reach within Brazil by targeting underserved regions and increasing its presence in key metropolitan areas. Investing in sales and marketing initiatives to promote its products in these regions can drive revenue growth. Brazil's diverse geographic landscape offers significant potential for Hypera to tap into new markets and customer segments.
- Leveraging Digital Channels: Hypera can leverage digital channels to enhance its marketing efforts and improve customer engagement. Investing in e-commerce platforms, social media marketing, and online advertising can drive brand awareness and increase sales. The growing adoption of digital technologies in Brazil presents a significant opportunity for Hypera to reach a wider audience and improve its customer experience.
- Strategic Partnerships and Collaborations: Hypera can pursue strategic partnerships and collaborations with other pharmaceutical companies, research institutions, and healthcare providers to expand its product portfolio and access new technologies. Collaborating with international companies can provide access to innovative products and markets. These partnerships can accelerate Hypera's growth and enhance its competitive position in the Brazilian pharmaceutical market.
Opportunities
- Expansion into new therapeutic areas.
- Strategic acquisitions and partnerships.
- Growth in the consumer health segment.
- Leveraging digital channels for marketing and sales.
Threats
- Increased competition from generic drug manufacturers.
- Changes in government regulations and healthcare policies.
- Economic downturn in Brazil.
- Patent expirations and loss of exclusivity.
Competitive Advantages
- Strong brand recognition for key products like Benegrip and Addera.
- Extensive distribution network across Brazil.
- Diversified product portfolio across multiple therapeutic areas.
- Established relationships with pharmacies and healthcare providers.
About HYPMY
Hypera S.A., formerly known as Hypermarcas S.A., was founded with the vision of becoming a leading pharmaceutical company in Brazil. The company has evolved through strategic acquisitions and organic growth, building a comprehensive portfolio of pharmaceutical products. Hypera operates in three primary segments: branded prescription drugs, consumer health products, and similar and generic medicines. Its branded prescription portfolio includes products like Adacne, Addera, and Celestamine, addressing various therapeutic areas. The consumer health segment features well-known brands such as Benegrip, Engov, and Epocler, catering to over-the-counter healthcare needs. Additionally, Hypera offers a range of generic medicines under the Neo Química brand, providing affordable treatment options. Hypera's dermo-cosmetics segment operates under the Mantecorp Skincare brand. The company has a strong distribution network across Brazil, ensuring its products are readily available to consumers. Hypera S.A. changed its name in February 2018 and is headquartered in São Paulo, Brazil, employing over 10,481 individuals.
What They Do
- Develops, manufactures, and markets a wide range of pharmaceutical products.
- Offers branded prescription drugs for various therapeutic areas.
- Provides over-the-counter consumer health products.
- Manufactures and distributes generic medicines.
- Offers dermo-cosmetic products under the Mantecorp Skincare brand.
- Provides nutritional and vitamin supplement products.
Business Model
- Develops and acquires pharmaceutical products.
- Manufactures products in its own facilities and through contract manufacturers.
- Distributes products through a network of pharmacies and retailers.
- Markets products through sales representatives and advertising campaigns.
Industry Context
Hypera S.A. operates within the Brazilian pharmaceutical industry, which is characterized by increasing demand for healthcare products and services. The market is driven by an aging population, rising disposable incomes, and growing awareness of health and wellness. The competitive landscape includes both domestic and international pharmaceutical companies. Hypera competes with companies like APNHF (Apotex Inc.), APNHY (Apotex Corp), BVNKF (Bayer AG), BVNRY (Bayer Corp), and DMPHF (Daiichi Sankyo), each vying for market share across various therapeutic areas. The industry is subject to regulatory oversight and pricing pressures, impacting profitability and growth strategies.
Key Customers
- Pharmacies and drugstores throughout Brazil.
- Hospitals and clinics.
- Individual consumers seeking prescription and over-the-counter medications.
- Healthcare providers who prescribe and recommend Hypera's products.
Financials
Chart & Info
Hypera S.A. (HYPMY) stock price: Price data unavailable
Latest News
-
Hypera SA (HYPMY) Q4 2025 Earnings Call Highlights: Record Cash Flow and Strategic Market Expansion
Yahoo! Finance: HYPMY News · Mar 21, 2026
-
Hypermarcas (OTCMKTS:HYPMY) Short Interest Update
defenseworld.net · Feb 12, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HYPMY.
Price Targets
Wall Street price target analysis for HYPMY.
MoonshotScore
What does this score mean?
The MoonshotScore rates HYPMY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Breno Toledo Pires de Oliveira
CEO
Breno Toledo Pires de Oliveira serves as the CEO of Hypera S.A., leading a workforce of over 10,481 employees. His professional background includes extensive experience in the pharmaceutical industry. He has held various leadership positions, demonstrating expertise in strategic planning, operational management, and business development. Oliveira's career reflects a commitment to driving growth and innovation within the healthcare sector. He is focused on strengthening Hypera's market position and expanding its product portfolio.
Track Record: Under Breno Toledo Pires de Oliveira's leadership, Hypera S.A. has focused on expanding its market share and diversifying its product offerings. Key milestones include strategic acquisitions and the introduction of innovative products in the consumer health segment. Oliveira has emphasized operational efficiency and cost management, contributing to improved profitability. His leadership has been instrumental in navigating the challenges of the Brazilian pharmaceutical market and positioning Hypera for continued growth.
Hypera S.A. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that are held by a U.S. depositary bank. HYPMY functions as a Level 1 ADR, meaning it trades on the over-the-counter (OTC) market. This allows U.S. investors to invest in Hypera S.A. without directly dealing with the Brazilian stock exchange.
- Home Market Ticker: HYPM - B3 (Brasil Bolsa Balcão), São Paulo, Brazil
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: HYPM
HYPMY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier typically have limited reporting requirements and may not meet the listing standards of major exchanges like the NYSE or NASDAQ. This tier is considered the most speculative due to the lack of regulatory oversight and potential for fraud. Investors should exercise extreme caution when considering investments in companies trading on the OTC Other tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and transparency.
- Potential for fraud and manipulation.
- Low trading volume and liquidity.
- Wide bid-ask spreads.
- Higher price volatility.
- Verify the company's registration and legal status.
- Attempt to obtain and review audited financial statements.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Be prepared to lose your entire investment.
- The company has been operating for a significant period of time.
- The company has a recognized brand name and established customer base.
- The company has a history of generating revenue and profits.
- The company is subject to some level of regulatory oversight in Brazil.
- The company has a board of directors and an audit committee.
What Investors Ask About Hypera S.A. (HYPMY)
What does Hypera S.A. do?
Hypera S.A. is a leading Brazilian pharmaceutical company that develops, manufactures, and markets a diverse range of pharmaceutical products. Its portfolio includes branded prescription drugs, over-the-counter consumer health products, generic medicines, and dermo-cosmetic products. The company operates primarily in Brazil, distributing its products through a network of pharmacies, hospitals, and retailers. Hypera focuses on providing affordable and accessible healthcare solutions to meet the needs of the Brazilian population.
What do analysts say about HYPMY stock?
Analyst coverage of HYPMY is limited due to its OTC listing and ADR Level 1 status. However, analysts generally view Hypera S.A. favorably due to its strong market position in Brazil, diversified product portfolio, and attractive dividend yield. Key valuation metrics include its P/E ratio of 11.78 and profit margin of 15.5%. Growth considerations include the company's expansion strategy, new product launches, and potential regulatory changes in the Brazilian pharmaceutical market. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.
What are the main risks for HYPMY?
The main risks for HYPMY include exposure to currency fluctuations between the U.S. dollar and the Brazilian real, competition from larger multinational pharmaceutical companies, and potential changes in government regulations and healthcare policies in Brazil. Additionally, patent expirations and loss of exclusivity on key products could impact revenue and profitability. Economic conditions in Brazil could also affect consumer spending on healthcare products. As an OTC-listed stock, HYPMY is subject to additional risks related to liquidity, transparency, and regulatory oversight.
What are the key factors to evaluate for HYPMY?
Hypera S.A. (HYPMY) currently holds an AI score of 45/100, indicating low score. Key strength: Diversified product portfolio across multiple segments.. Primary risk to monitor: Ongoing: Exposure to currency fluctuations between the U.S. dollar and the Brazilian real.. This is not financial advice.
How frequently does HYPMY data refresh on this page?
HYPMY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HYPMY's recent stock price performance?
Recent price movement in Hypera S.A. (HYPMY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio across multiple segments.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HYPMY overvalued or undervalued right now?
Determining whether Hypera S.A. (HYPMY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HYPMY?
Before investing in Hypera S.A. (HYPMY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis pending for HYPMY.